Novartis share price logo

Novartis

NYSE: NVS

Mega Cap

$151.25

-3.96

(-2.55%)

as on

Novartis Stock Performance

as on November 20, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $150.74
    $153.18
    downward going graph

    0.34%

    Downside

    1.28%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $123.24
    $170.46
    downward going graph

    18.52%

    Downside

    12.70%

    Upside

    downward going graph

Novartis share price movements today

Previous Close
$155.21
Open
$151.54
Volume
2.2M
Market Cap
$290.3B
Dividend Yield
2.98%
Day's Low - High
$150.74 - $153.18
52 Week Low - High
$123.24 - $170.46

Novartis Historical Returns

1 Month Return
+ 3.34 %
3 Month Return
-3.18 %
1 Year Return
+ 21.92 %
3 Year Return
+ 63.53 %
5 Year Return
+ 90.07 %

Novartis Stock Fundamentals & Key Indicators

Check Novartis market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$290.3B

EPS (TTM)

5.25

Dividend Yield

2.98%

Quarterly Earnings Growth YOY

-0.69%

PE Ratio (TTM)

30.52

Industry PE ratio

25.89

PEG Ratio

-1.05

EBITDA

21.8B

Revenue (TTM)

56.3B

Profit Margin

74.30%

Return On Equity TTM

24.24%

Novartis vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Novartis with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$290.3B90.07%30.5274.30%2.98%
StrongBuy$1.3T430.40%45.5483.63%0.49%
StrongBuy$517.6B146.05%50.0673.72%2.36%
Buy$680.2B71.61%42.3067.56%1.87%
StrongBuy$286.8B60.70%25.6177.59%1.76%

Stock Returns calculator for Novartis Stock including INR - Dollar returns

The Novartis stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Novartis investment value today

Current value as on today

₹1,25,247

Returns

₹25,247

(+25.25%)

Returns from Novartis Stock

₹18,804 (+18.8%)

Dollar Impact

₹6,442 (+6.44%)

Analyst Recommendation on Novartis Stock

Based on 4 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 4 analysts, 50% of analysts recommend a 'BUY' rating for Novartis. Average target price of $157.1

Novartis Share Price Target

Get share price movements and forecasts by analysts on Novartis.

What analysts predicted

3.72%UPSIDE

Target Price

$157.1

Current Price

$151.25

Analyzed by

4 Analysts

High

$180

Target

$157.10

Low

$136

Novartis target price $157.1, a slight upside of 3.72% compared to current price of $151.25. According to 4 analysts rating.

Indian Investors' Interest in Novartis Stock

Investment in Novartis Shares on INDmoney has dropped by -55.92% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-55.92% versus previous 30 day period

Search interest for Novartis Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-10% versus previous 30 day period

Novartis Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
12,872
13,172
13,558
13,620
14,836
14,358
13,334
13,524
14,417
15,029
Gross Profit
9,699
9,938
10,234
10,393
11,514
10,819
9,793
10,065
10,737
11,421
Operating Income
4,014
3,627
3,530
4,663
4,864
4,501
3,520
4,235
4,735
1,843
EBITDA
5,249
5,614
5,188
5,831
6,076
5,841
5,072
5,410
5,936
5,365
Interest Expense
245
266
273
270
293
281
303
343
462
468
Depreciation
1,162
1,965
1,628
1,154
1,256
1,364
1,551
1,228
1,200
3,580
Income Before Tax
3,841
3,385
3,285
4,407
4,531
4,196
3,217
3,839
4,271
1,317
Income Tax Expense
595
200
465
798
507
266
813
683
1,012
121
Net Income
3,246
3,189
2,818
3,606
4,041
3,928
2,408
3,156
3,266
1,202
Net Profit Margin
75.35%
75.45%
75.48%
76.31%
77.61%
75.35%
73.44%
74.42%
74.47%
75.99%

Novartis Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
Gross Profit
29,771
31,589
34,252
34,777
32,239
31,879
34,188
38,895
42,975
Operating Income
8,702
8,403
9,086
10,152
10,056
7,946
9,769
14,544
17,644
EBITDA
14,588
20,238
15,616
17,211
30,914
14,682
18,255
20,715
22,821
Interest Expense
802
973
902
921
905
834
876
1,036
1,144
Depreciation
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
Income Before Tax
9,102
14,095
8,940
9,878
24,530
7,177
9,123
13,640
16,352
Income Tax Expense
1,603
1,295
1,793
1,807
1,625
1,128
551
1,701
2,385
Net Income
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
Net Profit Margin
68.59%
68.52%
70.37%
69.70%
73.31%
73.35%
73.27%
75.20%
75.83%

Novartis Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
3,246
3,189
2,818
3,606
4,024
3,930
2,408
3,156
3,266
1,196
Operating Cash Flow
4,875
6,286
4,193
3,645
6,664
6,571
2,253
3,676
5,888
5,503
Investing Cash Flow
-3,207
-374
-3,033
330
-2,243
-860
-2,111
-11,736
-3,090
-1,746
Financing Cash Flow
-3,200
-382
-2,996
-8,548
-5,213
-2,789
1,713
3,579
-2,030
-2,464
Change in Cash
-1,566
5,706
-2,150
-4,393
-410
2,900
1,879
-4,558
739
1,254

Novartis Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
7,703
12,614
7,147
8,071
22,905
6,049
8,572
11,939
13,967
Operating Cash Flow
12,621
14,272
13,625
13,650
15,071
14,236
14,458
17,619
19,144
Investing Cash Flow
-3,119
-5,591
-2,226
-13,182
4,208
1,468
5,596
-7,513
-4,877
Financing Cash Flow
-7,733
-4,244
-13,627
-2,208
-16,264
-20,562
-14,278
-11,742
-14,867
Change in Cash
1,853
4,411
-2,159
-1,454
2,749
-4,890
5,876
-1,934
-24

Global Institutional Holdings in Novartis

Check out the Institutions with significant holdings in Novartis.

Funds
Holdings
Shares Held
Ken Fisher
0.82%
16762528
Theofanis Kolokotrones
0.32%
6585464
DFA INVESTMENT DIMENSIONS GROUP INC
0.24%
4948698
VANGUARD CHESTER FUNDS
0.21%
4252875
Dimensional
0.18%
3635126

Novartis News & Key Events

  • img

    Today's Timeline - 19 November

    Thu, 02:03 PM

    -

    Novartis raises blockbuster drug forecasts to $18 billion, driven by strong market performance, despite concerns over future growth sustainability.

    Thu, 08:08 PM

    -

    Novartis raises peak-sales guidance for Kesimpta, Scemblix, and Leqvio, highlighting strong commercial performance and a robust pipeline.

    Thu, 09:46 PM

    -

    Novartis targets 5% annual sales growth through 2031 despite patent expirations and aims for a 40% core operating margin by 2029.

  • img

    Today's Timeline - 19 November

    Fri, 02:42 AM

    -

    Novartis reaffirms sales targets for ianalumab in Sjögrens, discussing potential FDA label and maintaining confidence in major sales ambitions.

Insights on Novartis

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Novartis AG has shown consistent revenue growth over the last four quarters. Their revenue increased from $13.33 billion to $15.02 billion, reflecting an average quarterly growth of 3.9%.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, NVS has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 45.1% return, outperforming this stock by 20.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Novartis AG has seen a significant decline in its net profit over the last two quarters. The profit dropped from $3.26 billion to $1.20 billion, resulting in an average decrease of 63.2% per quarter.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, NVS stock has moved down by -0.7%

About Novartis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
OrganisationNovartis
HeadquartersLichtstrasse 35, Basel, BS, 4056, CH
IndustryDrug Manufacturers - General
CEOVasant Narasimhan

Key Management of Novartis

Name

Title

Mr. Victor Bulto

President of US

Dr. Patrick Horber M.D.

President of International

Mr. Mukul Mehta

Chief Financial Officer

Ms. Sloan Simpson

Global Head of Investor Relations

Dr. Vasant Narasimhan M.D.

Chief Executive Officer

Dr. Steffen Lang Ph.D.

President of Operations

Paul Penepent

Head of Group Financial Reporting and Accounting

Ms. Karen L. Hale

Chief Legal & Compliance Officer

Dr. Robert Kowalski Pharm.D.

Chief People & Organization Officer

Mr. Evan Beckman

Global Head of Translational Medicine at Novartis Institute for BioMedical Research

FAQs

What is Novartis share price today?

Novartis share price today is $151.25 as on at the close of the market. Novartis share today touched a day high of $153.18 and a low of $150.74.

What is the 52 week high and 52 week low for Novartis share?

Novartis share touched a 52 week high of $170.46 on and a 52 week low of $123.24 on . Novartis stock price today i.e. is closed at $151.25,which is 11.27% down from its 52 week high and 22.73% up from its 52 week low.

What is Novartis's market capitalisation today?

Novartis market capitalisation is $0.29T as on .

How to invest in Novartis Stock (NVS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Novartis on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Novartis Stock (NVS) from India?

Indian investors can start investing in Novartis (NVS) shares with as little as ₹93.29000091552734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹932.90 in Novartis stock (as per the Rupee-Dollar exchange rate as on ). Based on Novartis share’s latest price of $151.25 as on November 20, 2026 at 2:29 am IST, you will get 0.0661 shares of Novartis. Learn more about fractional shares .

What are the returns that Novartis has given to Indian investors in the last 5 years?

Novartis stock has given 90.07% share price returns and 26.33% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?